Background: HMV is established to reduce readmission and mortality in selected COPD patients with persistent hypercapnia after severe exacerbation. However, COPD heterogeneity leads to variation in clinical benefit and practice. Methods: We conducted a restrospective study of 40 COPD patients admitted to respiratory support unit(RSU) with type II respiratory failure (T2RF) requiring acute non-invasive ventilation between 1/12/2022 to 10/6/2023. Demographics, arterial blood gases, length of stay, inpatient mortality, 30-day readmission and HMV compliance were analysed. Results: 50% were male with mean age of 71. 16(40%) patients were established on HMV prior to admission. Baseline severity in acute T2RF was similar between groups (mean pH 7.26 vs 7.25; pCO2 9.89 vs 9.33kPa for HMV vs non-HMV). Most patients in HMV group had very severe to severe COPD, WHO performance status(PS)≥3 and BMI≥30, possibly contributing to higher 30-day readmission(30.7 vs 22.2%). Inpatient mortality was however lower in the HMV group(18.7% vs 25%). Length of stay ≤7 days(43.8 vs 45.8%) was similar between group. Among HMV users, 69% demonstrated good compliance(≥5h/night) and 93.7% were prescribed IPAP≥20cmH2O (mean 24.5cmH2O). Conclusion: Pre-existing HMV with good compliance and higher inspiratory pressures was associated with lower inpatient mortality during acute T2RF in severe COPD. Active identification of suitable candidates and optimisation of comorbidities may improve outcomes and support future larger studies. erj;68/suppl_70/PA3228/F1 F1 F1